Cyber Resilience Act guidance raises the stakes for connected product suppliers

Tern plc

The latest Cyber Resilience Act guidance makes the direction of travel clear for connected product manufacturers. Security now has to be built in from the start, maintained through the life of the product and backed by clear processes for risk management, vulnerability handling and ongoing support.

Companies can no longer treat security as a box-ticking exercise at launch. They need to show that products can stay secure after deployment, through updates, configuration changes, new integrations and extended use in the field. That raises the bar for execution and increases the importance of scalable security operations.

This is especially relevant in IoT and OT markets, where products often stay in service for years and depend on complex supply chains, third-party software and remote services. In that environment, weak processes create risk over time. Manual controls, fragmented systems and assumptions of trust become harder to defend when regulation expects continuous oversight.

Security decisions have to reflect how products work in the real world, including where they are deployed, what data they process, what systems they connect to and which threats they are likely to face. For businesses operating in connected-device markets, this points to the value of stronger device identity, trusted credentials and secure communications. Without those foundations, it becomes harder to enforce policy, manage updates securely or demonstrate that cyber risks are under control.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Talking Medicines highlights strategic signals emerging across the GLP-1 consumer market

GLP-1 consumers are increasingly weighing access, affordability, quality, clinical oversight and treatment support, creating new strategic considerations across the wider life sciences market.

Tern Plc launches £509,368 underwritten Open Offer

Tern Plc has announced an underwritten Open Offer to raise approximately £509,368 through the issue of 56.6 million shares at 0.90p each. Qualifying shareholders may subscribe for one new share for every 16 shares held, with the offer closing on 22 September 2026.

Talking Medicines targets a growing data need around GLP-1 treatment journeys

Talking Medicines is using GLP-1 discontinuation conversations to show how DrugVoice can help pharmaceutical companies track changing patient needs across the treatment journey.

Device Authority adopts usage-based pricing to support KeyScaler expansion

Device Authority has moved KeyScaler to usage-based pricing, aiming to reduce licensing friction and support broader adoption of its machine identity security platform.

Talking Medicines targets growing demand for GLP-1 patient intelligence

Talking Medicines is using GLP-1 patient conversations to show how behavioural data can help pharmaceutical companies understand changing treatment expectations and engagement.

Talking Medicines builds its AI strategy around specialist life sciences intelligence

Talking Medicines is positioning specialist healthcare intelligence as the core layer that gives agentic AI useful context in life sciences.

Search